dipyridamole has been researched along with Cholera Infantum in 8 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole was associated with fewer adverse events than regadenoson in patients undergoing MPI." | 1.46 | Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging. ( Amer, KA; Cohen, G; Edwin, SB; Hurren, JR, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amer, KA | 1 |
| Hurren, JR | 1 |
| Edwin, SB | 1 |
| Cohen, G | 1 |
| Morton, JA | 1 |
| Newton, J | 1 |
| Gray, CS | 1 |
| Fuster, V | 1 |
| Chesebro, JH | 1 |
| Culliton, BJ | 1 |
| Waterfall, WK | 1 |
| Köhne, CH | 1 |
| Hiddemann, W | 1 |
| Schüller, J | 1 |
| Weiss, J | 1 |
| Lohrmann, HP | 1 |
| Schmitz-Hübner, U | 1 |
| Bodenstein, H | 1 |
| Schöber, C | 1 |
| Wilke, H | 1 |
| Grem, J | 1 |
| Forbes, CD | 1 |
| Markman, M | 1 |
| Chan, TC | 1 |
| Cleary, S | 1 |
| Howell, SB | 1 |
| Abrahamsen, AF | 1 |
| Eika, C | 1 |
| Godal, HC | 1 |
| Lorentsen, E | 1 |
1 review available for dipyridamole and Cholera Infantum
| Article | Year |
|---|---|
10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts).
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Epoprostenol; Fibrinolytic Agents; Gastrointestina | 1981 |
3 trials available for dipyridamole and Cholera Infantum
| Article | Year |
|---|---|
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1995 |
European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Disease-Free Survival; Double-Blind Method; | 1997 |
Effect of acetylsalicylic acid and dipyridamole on platelet survival and aggregation in patients with atherosclerosis obliterans.
Topics: Aged; Arteriosclerosis Obliterans; Aspirin; Blood Cell Count; Blood Platelets; Cell Survival; Clinic | 1974 |
4 other studies available for dipyridamole and Cholera Infantum
| Article | Year |
|---|---|
Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
Topics: Adenosine A2 Receptor Agonists; Aged; Cohort Studies; Cost-Benefit Analysis; Dipyridamole; Dyspnea; | 2017 |
Counting the true cost of antiplatelet therapy for stroke prevention.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Dipyridam | 2005 |
Studies of myocardial infarction.
Topics: Aspirin; Dipyridamole; Drug Combinations; Gastrointestinal Diseases; Humans; Myocardial Infarction; | 1980 |
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyr | 1987 |